

Contents

Preface XIII

List of Contributors XIX

Part I Biochemical Studies 1

- 1 The Role of Copper Ion and the Ubiquitin System in Neurodegenerative Disorders** 3
Fabio Arnesano
 - 1.1 Introduction 3
 - 1.2 Metal Ions in the Brain 4
 - 1.3 Brain Copper Homeostasis 5
 - 1.4 Brain Copper and Neurodegenerative Disorders 8
 - 1.5 The Role of Ubiquitin in Protein Degradation 9
 - 1.6 Failure of the Ubiquitin System in Neurodegenerative Disorders 13
 - 1.7 Interaction of Ubiquitin with Metal Ions 15
 - 1.7.1 Thermal Stability of Ubiquitin 15
 - 1.7.2 Spectroscopic Characterization of Cu^{II} Binding 15
 - 1.7.3 Possible Implications for the Polyubiquitination Process 17
 - 1.7.4 Cu^{II}-Induced Self-Oligomerization of Ub 17
 - 1.7.5 Cooperativity between Cu^{II}-Binding and Solvent Polarity 18
 - 1.7.6 Comparison with Other Metal Ions 19
 - 1.8 Biological Implications 21
 - 1.8.1 The Redox State of Cellular Copper 21
 - 1.8.2 Ubiquitin and Phospholipids 22
 - 1.9 Conclusions and Perspectives 23
 - Acknowledgments 24
 - References 24
- 2 The Bioinorganic and Organometallic Chemistry of Copper(III)** 31
Xavi Ribas and Alicia Casitas
 - 2.1 Introduction 31
 - 2.2 Bioinorganic Implications of Copper(III) 33

2.2.1	Dinuclear Type-3 Copper Enzymes	33
2.2.2	Particulate Methano Monooxygenase (pMMO)	36
2.2.3	Mononuclear Monooxygenating Copper-based Enzymes	38
2.2.4	Trinuclear Copper Models for Laccase	40
2.3	Organometallic Cu ^{III} Species in Organic Transformations	41
2.3.1	C–C Bond Formation in Organocuprate(I) Catalysis	42
2.3.1.1	Conjugate Addition to α -Enones	42
2.3.1.2	Acetylene Carbocupration	43
2.3.1.3	S _N 2 and S _N 2' Alkylations	43
2.3.2	Aryl–Heteroatom Bond Formation in Cu-mediated Cross-coupling Processes	44
2.3.3	Aromatic and Aliphatic C–H Bond Organometallic Functionalizations	45
2.3.3.1	Catalytic Systems	45
2.3.3.2	Stoichiometric Systems	47
2.4	Miscellany: Cuprate Superconducting Materials	51
2.5	Overview and Future Targets	51
	References	52

3 Chemical Protein Modification 59

Gonçalo J. L. Bernardes, Justin M. Chalker, and Benjamin G. Davis

3.1	Introducing Diversity by Posttranslational Modification	59
3.2	Chemistry: A Route to Modified Proteins	60
3.3	Challenges in Chemical Protein Modification	61
3.4	Traditional Methods for Protein Modification	61
3.4.1	Lysine Modification	62
3.4.1.1	Activated Esters	62
3.4.1.2	Isocyanates and Isothiocyanates	62
3.4.1.3	Reductive Alkylation	62
3.4.1.4	IME Reagents	63
3.4.2	Glutamic and Aspartic Acid Modification	64
3.4.3	Cysteine	64
3.4.3.1	Alkylation	65
3.4.3.2	Disulfides	66
3.4.3.3	Desulfurization at Cysteine	67
3.5	Recent Innovations in Site-Selective Protein Modification	70
3.5.1	Dehydroalanine: A Useful Chemical Handle for Protein Conjugation	71
3.5.2	Metal-Mediated Protein Modification	71
3.5.2.1	Modification at Natural Residues	72
3.5.2.2	Iridium-Catalyzed Reductive Alkylation of Lysine	74
3.5.2.3	Modification of Unnatural Residues	74
3.5.2.4	Olefin Metathesis at S-Allyl Cysteine	77
3.5.3	Metal-Free Methods for Modifying Unnatural Amino Acids	78
3.5.3.1	Oxime Ligation at Aldehydes and Ketones	78

- 3.5.3.2 Azide and Alkyne Modification 79
- 3.5.3.3 Selective Modification of Tetrazole-Containing Proteins 80
- 3.5.3.4 Tetrazine Ligation 81
- 3.5.4 Dual Modification 81
- 3.6 Conclusion and Outlook 81
- References 82

Part II Drug Delivery 93

4 Vitamin B₁₂: A Potential Targeting Molecule for Therapeutic Drug Delivery 95

Pilar Ruiz-Sánchez

- 4.1 Introduction 95
- 4.2 Transport Mechanism 96
- 4.3 Metabolism of B₁₂ 97
- 4.3.1 Adenosylcobalamin-Dependent Reactions 97
- 4.3.2 Methylcobalamin-Dependent Reactions 99
- 4.4 Vitamin B₁₂ Derivatives 99
- 4.4.1 Structure 99
- 4.4.2 b-, d-, e-Cobalamin Derivatives 99
- 4.4.3 Modifications on the Ribose Moiety 101
- 4.4.4 β -Axial Position 102
- 4.4.4.1 Cobalamin Alkylation 102
- 4.4.4.2 Heterodinuclear Concept 103
- 4.5 Outlook 108
- Acknowledgments 108
- References 109

5 Strategies for Microsphere-Mediated Cellular Delivery 117

Rosario M. Sanchez-Martin, Lois M. Alexander, Juan Manuel Cardenas-Maestre, and Mark Bradley

- 5.1 Introduction 117
- 5.1.1 Cellular Delivery 117
- 5.1.2 Delivery Devices 117
- 5.1.2.1 Liposomes 117
- 5.1.2.2 Cell-penetrating Peptides 118
- 5.1.2.3 Dendrimers 118
- 5.1.2.4 Nanomaterials 118
- 5.2 Microspheres 119
- 5.2.1 Biodegradable Microspheres 119
- 5.2.1.1 Preparation 119
- 5.2.2 Biostable Microspheres 120
- 5.2.2.1 Applications of Biostable Microspheres 120
- 5.2.2.2 Preparation 120
- 5.2.3 Microspheres and Solid-phase Chemistry 121

5.2.3.1	Preparation of Microspheres	121
5.2.3.2	Fmoc Chemistry on Microspheres	121
5.2.3.3	Dual Functionality of Microspheres	122
5.2.3.4	Coupling Agents	124
5.2.4	Noncleavable Link to Microspheres	126
5.2.4.1	Microsphere-based Intracellular Sensing	126
5.2.4.2	siRNA Delivery	127
5.2.5	Cleavable Linkers	130
5.2.5.1	Ester Bonds	130
5.2.5.2	Disulfide Bonds	132
5.2.6	Bioconjugation	133
5.2.6.1	Streptavidin–Biotin	134
5.3	Future Perspectives	135
	Acknowledgments	135
	References	135
 Part III Research in Therapeutics 141		
6	Fundamental Processes in Radiation Damage to DNA: How Low-Energy Electrons Damage Biomolecules	143
	<i>Ilko Bald</i>	
6.1	Radiation Damage and the Role of Low-Energy Electrons	143
6.1.1	How Chemical Bonds are Broken by Low-energy Electrons	145
6.1.2	DEA Studies of Gas-Phase DNA Building Blocks: The Nucleobases	147
6.2	DEA Studies on Model Compounds for the DNA Backbone	148
6.2.1	Electron Attachment to D-Ribose	148
6.2.2	Cross-Ring Cleavage of D-Ribose Proceeds with Selective Charge Retention	150
6.2.3	The Nature of the Transient Negative D-Ribose Anions	154
6.2.4	One Step Further: Tetraacetyl-D-Ribose	155
6.2.5	The Use of Laser-Induced Acoustic Desorption (LIAD) to Study DEA to Larger Biomolecules	159
6.2.6	Sugar–Phosphate Cleavage Induced by 0 eV Electrons: DEA to D-Ribose-5'-Phosphate	159
6.3	Outlook and Future Prospects	161
	Acknowledgments	162
	References	163
 7	 Structure-Based Design on the Way to New Anti-infectives	 167
	<i>Anna Katharina Herta Hirsch</i>	
7.1	Introduction	167
7.2	Isoprenoids and the Nonmevalonate Pathway	169
7.2.1	4-Diphosphocytidyl-2C-methyl-D-erythritol Kinase (IspE)	170
7.2.2	Structure of IspE	170

7.2.3	Active Site of IspE	170
7.3	Targeting the CDP-Binding Pocket of IspE	174
7.3.1	Design	174
7.3.1.1	Possible Ribose Analogues	175
7.3.1.2	Design of the Vector	176
7.3.2	Optimization of the Ribose Analogue	176
7.3.3	Importance of the Vector	178
7.3.4	Optimization of the Filling of the Small, Hydrophobic Pocket	179
7.3.4.1	The "55% Rule"	179
7.3.4.2	Evaluation of Inhibitors Featuring Different Sulfone Substituents	180
7.3.5	Summary of the First-Generation Inhibitors	182
7.4	X-ray Cocrystal Structure Analysis	182
7.4.1	Design of Water-Soluble Inhibitors	182
7.4.2	Enzyme Assays of Inhibitors Designed to be Water Soluble	183
7.4.3	Structural Analysis	184
7.4.4	Lessons Learnt from the Cocrystal Structure	185
7.5	Conclusions and Outlook	185
7.5.1	Conclusions	185
7.5.2	Outlook	186
	Acknowledgments	186
	List of Abbreviations	186
	References	187
8	Drug–Membrane Interactions: Molecular Mechanisms Underlying Therapeutic and Toxic Effects of Drugs	191
	<i>Marlene Lúcio, José L. F. C. Lima, and Salette Reis</i>	
8.1	Biological Membranes	191
8.1.1	Role of Membranes in Life Maintenance	191
8.1.2	Structure and Composition of Membranes	191
8.1.3	Dynamic Molecular Organization of Membranes	193
8.2	Drug–Membrane Interactions	195
8.2.1	Possible Effects of Drugs on Membranes	195
8.2.2	Clinical Relevance of the Drug–Membrane Interaction Studies	195
8.2.2.1	Contribution for Drug Development	195
8.2.2.2	Understanding Therapeutic and Toxic Effect of Drugs	197
8.2.2.3	Understanding Mechanisms of Multidrug Resistance	198
8.2.2.4	Controlling Enzymatic Inhibition	198
8.3	Analysis and Quantification of Drug–Membrane Interactions	199
8.3.1	Membrane Model Systems	199
8.3.2	Experimental Techniques	200
8.4	Drug–Membrane Interactions Applied to the Study of Nonsteroidal Anti-inflammatory Drugs (NSAIDs)	201
8.4.1	Drug Fundamental Physical–Chemical Studies	202
8.4.2	Membrane Structural and Dynamic Studies	203

8.4.3	Results	205
8.5	Conclusions and Future Research Directions	206
	Acknowledgments	206
	References	207
9	Targeting Disease with Small Molecule Inhibitors of Protein-Protein Interactions	215
	<i>Fedor Forafonov, Elena Miranda, Ida Karin Nordgren, and Ali Tavassoli</i>	
9.1	Introduction	215
9.2	High-Throughput Screening of Chemical Libraries	216
9.3	High-Throughput Screening of Biosynthesized Libraries	220
9.3.1	Cyclic Peptide Inhibitors of AICAR Transformylase Activity	222
9.3.2	Cyclic Peptide Inhibitors of HIV Budding	224
9.4	Future Direction	226
9.4.1	Small Molecule Inhibitors of Tumor Hypoxia Response Network	226
9.4.2	Targeting Protein-Protein Interactions in Asthma	228
9.4.3	Targeting the Protein Interaction Networks of Influenza Virus	230
	Acknowledgments	232
	References	232
10	Cracking the Glycocode: Recent Developments in Glycomics	239
	<i>Lars Hillringhaus and Jürgen Seibel</i>	
10.1	State of the Art	239
10.1.1	Introduction	239
10.1.2	Carbohydrate-Based Drugs	239
10.1.3	Carbohydrate Synthesis	240
10.1.3.1	Chemical Synthesis	241
10.1.3.2	Enzymatic Synthesis	243
10.1.3.3	Glycoprotein Synthesis	244
10.1.4	Glycomics	245
10.1.4.1	Mass Spectrometry	245
10.1.4.2	Microarrays	246
10.1.4.3	Cell, Tissue, and Metabolic Labeling	246
10.1.4.4	Bioinformatics	247
10.2	Some New Insights in Glycomics	247
10.2.1	Microwave-Assisted Glycosylation for the Synthesis of Glycopeptides	247
10.2.2	Highly Efficient Chemoenzymatic Synthesis of Novel Branched Thioligosaccharides by Substrate Direction with Glucansucrases	251
10.2.3	Identification of New Acceptor Specificities of Glycosyltransferase R with the Aid of Substrate Microarrays	257
10.3	Future Perspectives	259
	Acknowledgments	259
	References	260

Part IV Enzyme Chemistry 265

- 11 O₂ Reactivity at Model Copper Systems: Mimicking Tyrosinase Activity 267**
Anna Company
- 11.1 General Introduction: O₂ Activation and Model Systems 267
- 11.2 Copper Proteins Involved in O₂ Activation 268
- 11.2.1 Hemocyanin 269
- 11.2.2 Tyrosinase 270
- 11.3 O₂ Binding and Activation at Biomimetic Cu Complexes 272
- 11.3.1 Copper–Dioxygen Adducts 272
- 11.3.2 Ligand Architecture: Influence on Reactivity toward O₂ 275
- 11.3.3 Hydroxylation of Aromatic Rings: Mimicking Tyrosinase Activity 278
- 11.3.3.1 Intramolecular Aromatic Hydroxylation 278
- 11.3.3.2 Intermolecular *ortho*-Hydroxylation of Phenolic Compounds 280
- 11.4 Concluding Remarks 285
- References 286

Part V Structure–Property Relationship and Biosensing 291

- 12 Chirality in Biochemistry: A Computational Approach for Investigating Biomolecule Conformations 293**
Adriana Pietropaolo
- 12.1 Introduction 293
- 12.1.1 Molecular Chirality in Living Systems 293
- 12.1.2 Protein Secondary Structures 295
- 12.1.3 Protein Secondary Structure Assignment 296
- 12.1.4 Intrinsic Chirality and Protein Secondary Structures 297
- 12.2 Computational Techniques for Studying Protein Dynamics 297
- 12.3 Employing Chirality to Analyze Protein Motions 298
- 12.3.1 The Chirality Index 298
- 12.3.2 Using Chirality to Understand Protein Structure 300
- 12.3.3 Chirality Index as a Tool for Monitoring Protein Dynamics 302
- 12.3.4 Chirality and Circular Dichroism 305
- 12.4 Perspectives 308
- Acknowledgments 309
- References 310
- 13 Collisional Mechanism–Based E-DNA Sensors: A General Platform for Label-Free Electrochemical Detection of Hybridization and DNA Binding Proteins 313**
Francesco Ricci
- 13.1 Introduction 313
- 13.2 E-DNA Signaling Mechanism 315
- 13.3 E-DNA Sensor for DNA Binding Proteins Detection 319

13.4	Conclusions and Future Perspectives	321
------	-------------------------------------	-----

13.5	Acknowledgments	324
------	-----------------	-----

	References	324
--	------------	-----

	Index	327
--	-------	-----